Not only is Hampton, NJ-based Celldex Therapeutics operating in the challenging cancer vaccines field, but it's working on a treatment for one of the most difficult-to-treat cancers. But with positive new Phase II survival data in hand, the company could eventually have a winner.
Shares of Celldex Therapeutics shot up 20% this morning after the biotech announced that the FDA had provided its breakthrough therapy designation for rindopepimut (Rintega), an experimental drug for patients with EGFRvIII-positive glioblastoma.
In a Phase II trial, Celldex Therapeutics' cancer vaccine rindopepimut, or Rintega, helped recurrent glioblastoma patients who took it with Roche's Avastin survive a median of 3.2 months longer than patients who took Avastin alone.
Bristol-Myers has one of the best drug development track records in the industry, and the big biotech is devoting major resources to its immuno-oncology lead. Bristol-Myers issued 5 new releases on nivolumab last night, and they all followed an early-morning statement on a new nivo combo study being mounted with Celldex.
The Needham, MA-based company's CDX-011 consists of an antibody targeted to the GPNMB protein and an attached chemotherapy agent that is supposed to hit tumor cells with a killer punch.
Celldex Therapeutics ($CLDX) reports that a small, single-arm study of its experimental brain cancer vaccine scored a significantly higher overall survival rate than the historical numbers on file.
Celldex Therapeutics ($CLDX) has unveiled overall survival data from a 65-person Phase II trial of the company's brain cancer vaccine rindopepimut. In the single-arm trial, the Needham, MA-based
Biotech stocks were rocked last week when Dendreon, which makes the only approved cancer vaccine, reported that sales of Provenge significantly missed their mark. Dendreon lost two-thirds of its
The executives at Celldex Therapeutics ($CLDX) may be asking themselves 'Who needs Pfizer, anyway?' as they gather at the water cooler this morning. Earlier this year, Celldex's shares took a beating
A new vaccine produced by Celldex Therapeutics--CDX-110--added to standard therapy appears to offer a survival advantage for patients suffering from glioblastoma, according to researchers at Duke